Letter abstract


Nature Medicine 14, 837 - 842 (2008)
Published online: 22 June 2008 | Corrected online: 15 July 2008 | doi:10.1038/nm1782

Amyloid-bold beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Ganesh M Shankar1,2, Shaomin Li1, Tapan H Mehta1, Amaya Garcia-Munoz3, Nina E Shepardson1, Imelda Smith4, Francesca M Brett5, Michael A Farrell5, Michael J Rowan6, Cynthia A Lemere1, Ciaran M Regan3, Dominic M Walsh4, Bernardo L Sabatini2 & Dennis J Selkoe1

Top

Alzheimer's disease constitutes a rising threat to public health. Despite extensive research in cellular and animal models, identifying the pathogenic agent present in the human brain and showing that it confers key features of Alzheimer's disease has not been achieved. We extracted soluble amyloid-beta protein (Abeta) oligomers directly from the cerebral cortex of subjects with Alzheimer's disease. The oligomers potently inhibited long-term potentiation (LTP), enhanced long-term depression (LTD) and reduced dendritic spine density in normal rodent hippocampus. Soluble Abeta from Alzheimer's disease brain also disrupted the memory of a learned behavior in normal rats. These various effects were specifically attributable to Abeta dimers. Mechanistically, metabotropic glutamate receptors were required for the LTD enhancement, and N-methyl D-aspartate receptors were required for the spine loss. Co-administering antibodies to the Abeta N-terminus prevented the LTP and LTD deficits, whereas antibodies to the midregion or C-terminus were less effective. Insoluble amyloid plaque cores from Alzheimer's disease cortex did not impair LTP unless they were first solubilized to release Abeta dimers, suggesting that plaque cores are largely inactive but sequester Abeta dimers that are synaptotoxic. We conclude that soluble Abeta oligomers extracted from Alzheimer's disease brains potently impair synapse structure and function and that dimers are the smallest synaptotoxic species.

Top
  1. Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.
  2. Department of Neurobiology, Harvard Medical School, 220 Longwood Avenue, Boston, Massachusetts 02115, USA.
  3. School of Biomolecular and Biomedical Science, University College Dublin, Dublin 4, Ireland.
  4. Laboratory for Neurodegenerative Research, University College Dublin, Dublin 4, Ireland.
  5. Department of Pathology, Beaumont Hospital and Royal College of Surgeons Ireland, Dublin 9, Ireland.
  6. Trinity College Institute of Neuroscience and Department of Pharmacology and Therapeutics, Trinity College, Dublin 2, Ireland.

Correspondence to: Dennis J Selkoe1 e-mail: dselkoe@rics.bwh.harvard.edu

* Nature Medicine; doi:10.1038/nm1782; published online 22 June 2008; corrected 15 July 2008. In the version of this article initially published online, the authors inadvertently included the blot in Figure 1b (right) a second time as Figure 1a (right). In addition, the authors would like to clarify the white areas within Figure 3a (top and bottom) in the figure legend. These errors have been corrected for all versions of the article.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

The synaptic Aβ hypothesis of Alzheimer disease

Nature Neuroscience News and Views (01 Aug 2005)

Medicine Danger ??? misfolding proteins

Nature News and Views (04 Apr 2002)